Assembly Bio's ABI-H2158 Fast Track'd in U.S. for hepatitis B infection
Jul. 9, 2020 8:31 AM ET|About: Assembly Biosciences, ... (ASMB)|By: Douglas W. House, SA News Editor
The FDA designates Assembly Biosciences' (NASDAQ:ASMB) Phase 2-stage ABI-H2158, a second-generation core inhibitor, for Fast Track review for the treatment of chronic hepatitis B virus (HBV) infection.
Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
Shares up 10% premarket on light volume.
Assembly Bio的ABI-H2158在美国快速跟踪乙肝感染
2020年7月9日,美国东部时间上午|关于:Assembly Biosciences,...(ASMB)|由:Douglas W. House,SA新闻编辑